Li, Ye https://orcid.org/0000-0001-7727-0875
Basar, Rafet
Wang, Guohui
Liu, Enli
Moyes, Judy S.
Li, Li
Kerbauy, Lucila N.
Uprety, Nadima
Fathi, Mohsen https://orcid.org/0000-0001-9971-4166
Rezvan, Ali https://orcid.org/0000-0002-1197-0198
Banerjee, Pinaki P.
Muniz-Feliciano, Luis
Laskowski, Tamara J.
Ensley, Emily
Daher, May
Shanley, Mayra
Mendt, Mayela
Acharya, Sunil
Liu, Bin
Biederstädt, Alexander https://orcid.org/0000-0003-2805-8231
Rafei, Hind
Guo, Xingliang
Melo Garcia, Luciana
Lin, Paul
Ang, Sonny
Marin, David
Chen, Ken https://orcid.org/0000-0003-4013-5279
Bover, Laura
Champlin, Richard E.
Varadarajan, Navin
Shpall, Elizabeth J.
Rezvani, Katayoun https://orcid.org/0000-0002-9599-2246
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA211044-01, 5 P01CA148600-03, P50CA100632-16, R01GM143243, P50CA100632, P30 CA016672, CA016672)
EIF | Stand Up To Cancer (SU2C-AACR-DT-29-19)
Article History
Received: 15 December 2021
Accepted: 9 August 2022
First Online: 29 September 2022
Change Date: 5 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-023-02770-1
Competing interests
: R.B., E.L., L.N.K., P.P.B., S.A., D.M., M.D., P.L., R.E.C., E.J.S., K.R. and The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical. S.A., D.M., R.B., E.L., L.N.K., E.J.S., K.R. and The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Affimed GmbH. K.R. participates on the Scientific Advisory Board for GemoAb, AvengeBio, Virogin Biotech, GSK, Caribou Biosciences, Navan Technologies and Bayer. N.V. is a founder of CellChorus. The remaining authors declare no competing interests.